Innovent Biologics Inc
HKEX:1801
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
30.1
51.15
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Innovent Biologics Inc
Innovent Biologics Inc
Total Liabilities
Innovent Biologics Inc
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Innovent Biologics Inc
HKEX:1801
|
Total Liabilities
¥7.9B
|
CAGR 3-Years
20%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Total Liabilities
¥16B
|
CAGR 3-Years
13%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Total Liabilities
¥3B
|
CAGR 3-Years
47%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Total Liabilities
¥1.6B
|
CAGR 3-Years
27%
|
CAGR 5-Years
35%
|
CAGR 10-Years
12%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Total Liabilities
¥23.3B
|
CAGR 3-Years
32%
|
CAGR 5-Years
39%
|
CAGR 10-Years
62%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Total Liabilities
¥504.4m
|
CAGR 3-Years
72%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
Innovent Biologics Inc
Glance View
Innovent Biologics Inc. is a dynamic, fast-growing biopharmaceutical company based in China, dedicated to the development and commercialization of innovative therapies for cancer and other serious diseases. Founded in 2011, Innovent has rapidly established itself as a key player in the biopharma sector, fueled by a commitment to creating high-quality monoclonal antibodies and biologic products. The company’s flagship product, IBI308, a PD-1 inhibitor, has received widespread attention and is already being used in clinical settings, reflecting Innovent's robust pipeline and its ability to bring novel treatments to market efficiently. With strategic partnerships and collaborations, particularly with global pharmaceutical giants, Innovent not only enhances its research capabilities but also facilitates a broader reach for its innovative therapies. For investors, Innovent presents a compelling opportunity within the burgeoning biopharmaceutical landscape, particularly as the global demand for targeted cancer therapies continues to grow. The company has demonstrated impressive growth metrics, showcasing its ability to secure funding, advance clinical trials, and expand its product offerings. With a scalable business model and a strong emphasis on R&D, Innovent is well-positioned to capitalize on the increasing focus on precision medicine. As it strives to enhance patient outcomes while navigating the complexities of regulatory approvals, Innovent promises to be a key player in the evolution of therapeutic options, potentially offering significant returns for those willing to invest in its vision of transforming healthcare in China and beyond.
See Also
What is Innovent Biologics Inc's Total Liabilities?
Total Liabilities
7.9B
CNY
Based on the financial report for Jun 30, 2024, Innovent Biologics Inc's Total Liabilities amounts to 7.9B CNY.
What is Innovent Biologics Inc's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
31%
Over the last year, the Total Liabilities growth was 11%. The average annual Total Liabilities growth rates for Innovent Biologics Inc have been 20% over the past three years , 31% over the past five years .
You don't have any saved screeners yet
